MedinGlobal

Edit Template

CYTOGEM 1GM

In Stock

CYTOGEM 1GM contains Gemcitabine (1000mg), an anticancer medicine belonging to the nucleoside analog chemotherapy class. It may be prescribed for selected pancreatic, lung, bladder, breast or ovarian cancers depending on the treatment protocol. Its active ingredient interferes with DNA synthesis in dividing cancer cells. Treatment requires specialist supervision and appropriate monitoring of blood counts, liver and kidney function and infusion-related toxicity.

Medinglobal provides product information and medicine enquiry coordination. Availability and any subsequent supply are subject to confirmation by an authorised independent provider and applicable regulations.

CYTOGEM 1GM – Composition, Uses and Medicine Enquiries

Product Overview

CYTOGEM 1GM is listed as a prescription product containing Gemcitabine (1000mg), marketed by Dr Reddy’s Laboratories Ltd. It belongs to the anticancer and nucleoside analog chemotherapy class and may be prescribed for selected pancreatic, lung, bladder, breast or ovarian cancers depending on the treatment protocol.

The active medicine interferes with DNA synthesis in dividing cancer cells.

Treatment suitability depends on the confirmed diagnosis, previous treatment, organ function and other medicines. The exact manufacturer pack, formulation, approved indication and administration schedule must be checked before treatment or publication.

A qualified clinician should assess suitability, interactions, contraindications and monitoring requirements. Blood counts, liver and kidney function and infusion-related toxicity require monitoring.

Composition and Strength

Active Ingredient Strength
Gemcitabine 1000 mg (1 gm)

Product Name: CYTOGEM 1GM

Generic Name: Gemcitabine

Brand Name: CYTOGEM 1GM

Strength: 1000 mg (1 gm)

Listed Marketer: Dr Reddy’s Laboratories Ltd

The exact formulation and product presentation should be verified against the original manufacturer packaging.

Therapeutic Category and Indication

CYTOGEM 1GM belongs to the anticancer medicine category and is classified as nucleoside analog chemotherapy.

It may be prescribed for selected pancreatic, lung, bladder, breast or ovarian cancers depending on the treatment protocol.

Gemcitabine works by interfering with DNA synthesis in dividing cancer cells.

The appropriate treatment protocol depends on the confirmed diagnosis, previous treatment, organ function and other medicines. The treating oncology specialist determines the benefit-risk balance and monitoring plan.

Administration Information

CYTOGEM 1GM is listed for intravenous infusion in a supervised oncology facility.

The treating clinician determines the appropriate administration schedule and monitoring requirements.

Patients should follow the approved product label and the oncology team’s instructions. They should not independently adjust the dose, skip safety monitoring or switch formulations without medical advice.

Product Presentation and Availability

The product enquiry can be made using the following details:

  • Product Name: CYTOGEM 1GM
  • Generic Name: Gemcitabine
  • Strength: 1000 mg (1 gm)
  • Therapeutic Category: Anticancer
  • Medicine Class: Nucleoside Analog Chemotherapy
  • Manufacturer Listed: Dr Reddy’s Laboratories Ltd
  • Administration: Intravenous infusion

The exact dosage form, pack size, batch, storage, expiry and product-specific presentation must be verified from the original manufacturer packaging and an authorised provider.

Product details and supply eligibility may vary by country.

Prescription and Patient Safety

CYTOGEM 1GM is a prescription anticancer medicine that requires supervision by a qualified oncology specialist.

Treatment requires individual clinical assessment and appropriate monitoring.

Blood counts, liver and kidney function and infusion-related toxicity require monitoring. The treating specialist should assess potential interactions, contraindications and the patient’s overall clinical condition.

The exact precautions and monitoring requirements should be checked against the current approved product information.

Medicine Enquiry Coordination Through Medinglobal

Medinglobal is a healthcare coordination platform. It can receive medicine information requests and, where legally permissible, connect patients or institutions with appropriately authorised independent pharmaceutical providers.

Medinglobal does not itself sell, dispense, manufacture or export CYTOGEM 1GM.

Product availability, lawful supply, prescription validation, commercial terms and destination requirements must be verified by the independent provider. Submitting an enquiry does not guarantee fulfilment.

How to Submit a CYTOGEM 1GM Enquiry

To help identify the requested product, include the following details:

  1. Product or brand name: CYTOGEM 1GM.
  2. Generic name: Gemcitabine.
  3. Required strength and formulation.
  4. Required quantity.
  5. Destination country.
  6. Prescription or institutional documents, where required.

Medinglobal may coordinate an introduction to a suitably authorised provider, who independently verifies product details, regulatory eligibility and any transaction.

Frequently Asked Questions

What is CYTOGEM 1GM used for?

It may be used for selected pancreatic, lung, bladder, breast or ovarian cancers depending on the treatment protocol. The treating prescriber confirms the approved use.

What is the composition of CYTOGEM 1GM?

The supplied product information lists Gemcitabine 1000mg as its active ingredient.

How is CYTOGEM 1GM administered?

It is administered through intravenous infusion in a supervised oncology facility.

Which company markets CYTOGEM 1GM?

The supplied product catalogue lists Dr Reddy’s Laboratories Ltd.

What precautions are associated with CYTOGEM 1GM?

Blood counts, liver and kidney function and infusion-related toxicity require monitoring during treatment.

Can Medinglobal supply CYTOGEM 1GM directly?

No. Medinglobal coordinates medicine enquiries with independent authorised providers where legally permissible.

Product Name

Generic Name

Brand Name

Composition

Strength

Therapeutic Category

Medicine Class

Indication

Dosage Form

Route of Administration

Reviews

There are no reviews yet.

Be the first to review “CYTOGEM 1GM”

Your email address will not be published. Required fields are marked *

Pharmaceutical Disclaimer

Medinglobal Platform does not sell, dispense, manufacture or prescribe medicines. Pharmaceutical information on this page is provided solely for general information, product identification and enquiry coordination. Product listing is not medical advice, a recommendation or an offer for sale by Teji Radiance or the Medinglobal Partnership Firm. Prescription medicines require a valid prescription where applicable. Any regulated pharmaceutical activity is undertaken by the relevant independent provider subject to applicable law. Always consult an appropriately qualified healthcare professional before using or changing any medicine.

Scroll to Top